Jagsonpal Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
Jagsonpal Pharmaceuticals has been growing earnings at an average annual rate of 28.9%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 9.6% per year. Jagsonpal Pharmaceuticals's return on equity is 14.5%, and it has net margins of 11.1%.
Key information
28.9%
Earnings growth rate
28.9%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 9.6% |
Return on equity | 14.5% |
Net Margin | 11.1% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump
Apr 30A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
Apr 05Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking
Feb 06Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
Jul 29A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
May 13Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?
Jul 05A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
Jun 13Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting
Apr 19Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?
Mar 21Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?
Feb 08The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio
Jan 08Here's Why I Think Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Is An Interesting Stock
Dec 21Are Jagsonpal Pharmaceuticals's (NSE:JAGSNPHARM) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Nov 30Revenue & Expenses BreakdownBeta
How Jagsonpal Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 2,207 | 245 | 828 | 0 |
30 Sep 23 | 2,336 | 283 | 867 | 0 |
30 Jun 23 | 2,363 | 313 | 682 | 0 |
31 Mar 23 | 2,367 | 267 | 827 | 0 |
31 Dec 22 | 2,410 | 223 | 767 | 0 |
30 Sep 22 | 2,348 | 198 | 736 | 0 |
30 Jun 22 | 2,326 | 131 | 582 | 0 |
31 Mar 22 | 2,176 | 189 | 704 | 0 |
31 Dec 21 | 2,168 | 247 | 689 | 0 |
30 Sep 21 | 2,194 | 247 | 691 | 0 |
30 Jun 21 | 2,163 | 214 | 565 | 0 |
31 Mar 21 | 1,879 | 171 | 659 | 0 |
31 Dec 20 | 1,746 | 135 | 550 | 0 |
30 Sep 20 | 1,595 | 104 | 543 | 0 |
30 Jun 20 | 1,450 | 84 | 490 | 0 |
31 Mar 20 | 1,586 | 79 | 687 | 0 |
31 Dec 19 | 1,675 | 93 | 525 | 0 |
30 Sep 19 | 1,673 | 88 | 506 | 0 |
30 Jun 19 | 1,697 | 85 | 491 | 0 |
31 Mar 19 | 1,668 | 72 | 483 | 0 |
31 Dec 18 | 1,611 | 30 | 484 | 0 |
30 Sep 18 | 1,573 | -10 | 460 | 0 |
30 Jun 18 | 1,421 | -66 | 444 | 0 |
31 Mar 18 | 1,266 | -116 | 434 | 0 |
31 Dec 17 | 1,234 | -95 | 425 | 0 |
30 Sep 17 | 1,193 | 26 | 418 | 0 |
30 Jun 17 | 1,305 | 70 | 394 | 0 |
01 Apr 17 | 1,441 | 119 | 424 | 0 |
31 Dec 16 | 1,534 | 131 | 435 | 0 |
30 Sep 16 | 1,537 | 35 | 431 | 0 |
30 Jun 16 | 1,466 | 34 | 408 | 0 |
31 Mar 16 | 1,435 | 33 | 397 | 0 |
31 Dec 15 | 1,434 | 13 | 564 | 0 |
30 Sep 15 | 1,412 | 10 | 546 | 0 |
30 Jun 15 | 1,412 | 9 | 314 | 0 |
31 Mar 15 | 1,382 | 12 | 334 | 0 |
31 Dec 14 | 1,306 | 23 | 568 | 0 |
30 Sep 14 | 1,359 | 32 | 585 | 0 |
30 Jun 14 | 1,397 | 28 | 468 | 0 |
31 Mar 14 | 1,439 | 21 | 605 | 0 |
31 Dec 13 | 1,507 | 12 | 610 | 0 |
30 Sep 13 | 1,623 | 14 | 617 | 0 |
30 Jun 13 | 1,673 | 18 | 373 | 0 |
Quality Earnings: JAGSNPHARM has high quality earnings.
Growing Profit Margin: JAGSNPHARM's current net profit margins (11.1%) are higher than last year (9.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: JAGSNPHARM's earnings have grown significantly by 28.9% per year over the past 5 years.
Accelerating Growth: JAGSNPHARM's earnings growth over the past year (10.1%) is below its 5-year average (28.9% per year).
Earnings vs Industry: JAGSNPHARM earnings growth over the past year (10.1%) did not outperform the Pharmaceuticals industry 23.3%.
Return on Equity
High ROE: JAGSNPHARM's Return on Equity (14.5%) is considered low.